{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:03:01Z","timestamp":1756810981199},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study intended to investigate the impact of long\u2010term\u00a0tenofovir fumarate (TDF) antiviral regimen on renal function in human immunodeficiency virus (HIV)\u2010infected patients with low\u2010risk of kidney injury. The observational study involving 100 HIV\u2010infected patients without underlying diseases who achieved virological suppression and immunological recovery after sustained antiviral regimen of TDF+ lamivudine+ efavirenz (TLE) for 3.19 years. Renal function, including estimated glomerular filtration rate (eGFR), blood and urine \u03b22 microglobulin, and other parameters, was assessed every 3 months over a period of 2.5 years. The eGFR showed a slight increasement from 116.0 at month 0 to 119.7 at month 30. Blood \u03b22 microglobulin increased from 2.02 mg\/L at month 0 to 2.77 mg\/L at month 30. Compared to month 0, the difference in blood \u03b22 microglobulin was statistically significant at month 6 and months 12\u201030 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05). The incidence of proximal renal tubular dysfunction fluctuated from 2% at month 0 to 2.5% at month 30. The urine \u03b22 microglobulin fluctuated from 0.5 (0.3\u20101.1) to 0.8 (0.5\u20101.35) mg\/L at months 18\u201030, which was higher than 0.41 (0.18\u20101.1) mg\/L at month 0 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05). The abnormal concentration proportion of urine \u03b22 microglobulin fluctuated from 72.7% to 81.3% at months 18\u201030, which was higher than the proportion of 57.0% at month 0. The abnormal proportion of blood \u03b22 microglobulin, urine \u03b22 microglobulin, and proximal renal tubular dysfunction were not correlated with eGFR (r1 = 0.119, r2 = \u22120.008, r3 = \u22120.165, <jats:italic>P<\/jats:italic>\u00a0&gt;\u00a0.05). Long\u2010term TDF antiviral regimen in low\u2010risk of kidney injury HIV\u2010infected patients may lead to damage in the proximal renal tubules and glomeruli. Blood and urine \u03b22 microglobulin levels may be helpful in screening for renal dysfunction.<\/jats:p>","DOI":"10.1002\/jcph.2403","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:27:56Z","timestamp":1707305276000},"page":"626-633","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Prolonged Administration of Tenofovir Disoproxil Fumarate\u2010Containing Antiviral Regimen on Renal Function in Low\u2010Risk of Kidney Injury HIV Patients"],"prefix":"10.1002","volume":"64","author":[{"given":"Yuan","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrong","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Infection Public Health Clinical Center of Chengdu  Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organization (WHO).HIV\/AIDS. Accessed March 23 2022.https:\/\/wwwwhoint\/news\u2010room\/fact\u2010sheets\/detail\/hiv\u2010aids"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2005.03.006"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw097"},{"issue":"1","key":"e_1_2_12_5_1","first-page":"50","article-title":"CROI 2019: advances in antiretroviral therapy","volume":"27","author":"Taylor BS","year":"2019","journal-title":"Top Antivir Med"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.06.002"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.07.008"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.01.022"},{"key":"e_1_2_12_9_1","unstructured":"KadirovichBA.Efficacy and safety of highly active antiretroviral therapy comprising tenofovir in patients with HIV infection.Sectiom 6. Medical science.2016;10.20534\/ESR\u201016\u20109.10\u201079\u201081."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.36924"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10051012"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012080857"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1712-z"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh658"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280b07b33"},{"key":"e_1_2_12_16_1","first-page":"4","article-title":"Nephrotoxicity of tenofovir in HIV\/AIDS patients (in Chinese)","volume":"9","author":"Geng TR","year":"2016","journal-title":"Chin J Intern Med"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109707300676"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu617"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328339fe53"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00211-8"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2016.370"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000347"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2016.0286"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/655681"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.2478\/v10011-010-0046-3"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002114"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0576-y"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001070"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz081"},{"key":"e_1_2_12_30_1","unstructured":"ZhaoBB.Clinical characteristics and risk factors of secondary renal proximal tubule injury. Peking Union Medical College;2020."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181be6be2"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T07:59:47Z","timestamp":1713945587000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/jcph.2403"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2403","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"2023-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}